Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Determinants of Female Sexual Dysfunction, and Its Association With Neurotrophic Biomarkers in Gynaecological Cancer Survivors: A Cross-Sectional Study.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Endometrial Stromal Sarcoma With Tumor Thrombus: A Rare Manifestation.

The journal of obstetrics and gynaecology research·2026
Same author

Clinical Validation of Four Point-of-Care High-Risk HPV Assays, Including Two Reduced-Valency Assays, for Cervical Cancer Screening in Low-Resource Settings.

International journal of cancer·2026
Same author

Live surgical workshops: Balancing patient care and professional development.

The National medical journal of India·2026
Same author

AOGIN India Policy Statement on the Use of HPV Vaccination for Cervical Cancer Elimination.

Asian Pacific journal of cancer prevention : APJCP·2026
Same author

Role of ascitic and peritoneal fluid effusion cytology in predicting intraperitoneal metastasis of malignant ovarian germ cell tumours.

Journal of the American Society of Cytopathology·2026

Related Experiment Video

Updated: Jul 13, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Multiple myeloma.

Seema Singhal1, Jayesh Mehta

  • 1Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA. s-singhal@northwestern.edu

Clinical Journal of the American Society of Nephrology : CJASN
|August 21, 2007
PubMed
Summary

Multiple myeloma is a complex cancer affecting plasma cells, leading to various symptoms and requiring intensive treatment. Newer therapies offer improved outcomes for relapsed disease, with ongoing research focusing on earlier intervention and personalized medicine.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jul 13, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Multiple myeloma is a plasma cell malignancy with characteristic symptoms like bone lesions and renal impairment.
  • Pathophysiology involves immune suppression, elevated Interleukin-6 (IL-6), bone marrow microenvironment abnormalities, and increased osteoclastic activity.
  • Prognostic indicators include albumin, beta2-microglobulin, and chromosomal karyotype.

Purpose of the Study:

  • To summarize the key features, pathophysiology, and treatment landscape of multiple myeloma.
  • To highlight the impact of novel therapeutic agents on relapsed disease.
  • To outline current research directions in multiple myeloma therapy.

Main Methods:

  • Review of existing literature on multiple myeloma.
  • Analysis of pathophysiologic mechanisms and prognostic factors.
  • Evaluation of therapeutic advancements, including novel agents and stem cell transplantation.

Main Results:

  • Modern intensive therapies, including autologous hematopoietic stem cell transplantation, yield a median survival of approximately 5 years.
  • Novel agents like thalidomide, bortezomib, and lenalidomide have significantly improved outcomes for relapsed multiple myeloma.
  • Despite advancements, multiple myeloma remains incurable, necessitating salvage therapies upon relapse.

Conclusions:

  • Therapeutic strategies for multiple myeloma are evolving, with a focus on integrating novel agents earlier in treatment.
  • Future research aims to develop targeted therapies and utilize gene expression profiling for personalized treatment approaches.
  • Continued investigation into the complex pathophysiology is crucial for improving patient survival and quality of life.